$OCUL
OCULAR THERAPEUTIX, INC

2020 Q4 Form 10-Q Financial Statement

#000155837020012870 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $7.350M $5.876M $829.0K
YoY Change 225.22% 608.81% 65.8%
Cost Of Revenue $680.0K $450.0K $806.0K
YoY Change -19.05% -44.17% 571.67%
Gross Profit $6.670M $5.426M $23.00K
YoY Change 369.72% 23491.3% -93.95%
Gross Profit Margin 90.75% 92.34% 2.77%
Selling, General & Admin $13.39M $12.48M $12.93M
YoY Change 5.52% -3.49% 134.7%
% of Gross Profit 200.75% 230.02% 56226.09%
Research & Development $7.620M $6.951M $10.24M
YoY Change -24.78% -32.09% 5.62%
% of Gross Profit 114.24% 128.11% 44500.0%
Depreciation & Amortization $660.0K $670.0K $670.0K
YoY Change -1.49% 0.0% 17.54%
% of Gross Profit 9.9% 12.35% 2913.04%
Operating Expenses $21.01M $19.43M $23.17M
YoY Change -7.93% -16.12% 52.51%
Operating Profit -$14.34M -$14.01M -$23.14M
YoY Change -32.99% -39.48% 56.27%
Interest Expense -$71.27M $1.715M $1.651M
YoY Change 1442.64% 3.88% -968.95%
% of Operating Profit
Other Income/Expense, Net $2.062M $4.366M
YoY Change -52.77%
Pretax Income -$85.61M -$11.94M -$18.78M
YoY Change 229.02% -36.42% 25.12%
Income Tax
% Of Pretax Income
Net Earnings -$85.61M -$11.94M -$18.78M
YoY Change 229.02% -36.39% 25.1%
Net Earnings / Revenue -1164.76% -203.27% -2265.14%
Basic Earnings Per Share -$0.19 -$0.40
Diluted Earnings Per Share -$1.211M -$0.21 -$0.45
COMMON SHARES
Basic Shares Outstanding 71.39M 62.99M 46.94M
Diluted Shares Outstanding 68.76M 52.71M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $228.1M $70.60M $65.40M
YoY Change 319.3% 7.95% 14.94%
Cash & Equivalents $228.1M $70.64M $65.41M
Short-Term Investments
Other Short-Term Assets $4.700M $2.300M $2.200M
YoY Change 113.64% 4.55% 100.0%
Inventory $1.201M $1.154M $900.0K
Prepaid Expenses
Receivables $12.25M $7.779M $1.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $246.2M $81.90M $69.60M
YoY Change 309.11% 17.68% 19.38%
LONG-TERM ASSETS
Property, Plant & Equipment $8.095M $8.490M $17.30M
YoY Change -20.25% -50.92% 66.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $1.800M $1.800M
YoY Change 0.0% 0.0% 12.5%
Total Long-Term Assets $15.70M $16.32M $19.10M
YoY Change -15.44% -14.58% 59.17%
TOTAL ASSETS
Total Short-Term Assets $246.2M $81.90M $69.60M
Total Long-Term Assets $15.70M $16.32M $19.10M
Total Assets $261.9M $98.22M $88.70M
YoY Change 232.57% 10.73% 26.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.709M $3.238M $3.500M
YoY Change -17.11% -7.49% 25.0%
Accrued Expenses $14.31M $12.17M $7.500M
YoY Change 87.39% 62.2% 66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.300M $6.200M
YoY Change
Total Short-Term Liabilities $26.66M $22.91M $11.00M
YoY Change 121.66% 108.24% -17.91%
LONG-TERM LIABILITIES
Long-Term Debt $41.20M $42.80M $48.10M
YoY Change -16.43% -11.02% 493.83%
Other Long-Term Liabilities $117.9M $36.70M $18.30M
YoY Change 461.43% 100.55% 454.55%
Total Long-Term Liabilities $159.1M $79.50M $66.40M
YoY Change 126.32% 19.73% 482.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.66M $22.91M $11.00M
Total Long-Term Liabilities $159.1M $79.50M $66.40M
Total Liabilities $185.8M $102.3M $77.40M
YoY Change 125.53% 32.23% 212.1%
SHAREHOLDERS EQUITY
Retained Earnings -$539.3M -$453.6M
YoY Change 40.57%
Common Stock $615.3M $449.5M
YoY Change 61.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.10M -$4.126M $11.30M
YoY Change
Total Liabilities & Shareholders Equity $261.9M $98.22M $88.70M
YoY Change 232.57% 10.73% 26.17%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$85.61M -$11.94M -$18.78M
YoY Change 229.02% -36.39% 25.1%
Depreciation, Depletion And Amortization $660.0K $670.0K $670.0K
YoY Change -1.49% 0.0% 17.54%
Cash From Operating Activities -$6.240M -$13.66M -$19.54M
YoY Change -67.95% -30.09% 79.76%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K -$220.0K -$420.0K
YoY Change -58.33% -47.62% -10.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$250.0K -$220.0K -$420.0K
YoY Change -58.33% -47.62% -10.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $75.41M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 163.9M 220.0K 18.61M
YoY Change 1703.19% -98.82% 63.68%
NET CHANGE
Cash From Operating Activities -6.240M -13.66M -19.54M
Cash From Investing Activities -250.0K -220.0K -420.0K
Cash From Financing Activities 163.9M 220.0K 18.61M
Net Change In Cash 157.4M -13.66M -1.350M
YoY Change -1533.7% 911.85% -4600.0%
FREE CASH FLOW
Cash From Operating Activities -$6.240M -$13.66M -$19.54M
Capital Expenditures -$250.0K -$220.0K -$420.0K
Free Cash Flow -$5.990M -$13.44M -$19.12M
YoY Change -68.26% -29.71% 83.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50333559
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63070980
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71391376
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70642000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54437000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7779000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2548000
CY2020Q3 us-gaap Inventory Net
InventoryNet
1154000
CY2019Q4 us-gaap Inventory Net
InventoryNet
954000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2328000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2231000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
81903000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
60170000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8490000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10151000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6062000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6655000
CY2020Q3 us-gaap Assets
Assets
98219000
CY2019Q4 us-gaap Assets
Assets
78740000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3238000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3268000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12165000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7635000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1297000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1126000
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
6206000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22906000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12029000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7909000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8905000
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
28764000
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
12124000
CY2020Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
18964000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25007000
CY2020Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
23802000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
24305000
CY2020Q3 us-gaap Liabilities
Liabilities
102345000
CY2019Q4 us-gaap Liabilities
Liabilities
82370000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63070980
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50333559
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
449507000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
379980000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453639000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383615000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4126000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3630000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10235000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21070000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30966000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6520000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6777000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19803000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17349000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5961000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98219000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78740000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
806000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1403000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1486000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6951000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5876000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
829000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10054000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1971000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5876000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
829000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10054000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1971000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
450000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6155000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16282000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16571000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
19882000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
23973000
us-gaap Costs And Expenses
CostsAndExpenses
58558000
us-gaap Costs And Expenses
CostsAndExpenses
66372000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14006000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23144000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48504000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64401000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
6000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
308000
us-gaap Investment Income Net
InvestmentIncomeNet
162000
us-gaap Investment Income Net
InvestmentIncomeNet
1016000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1715000
CY2019Q3 us-gaap Interest Expense
InterestExpense
1651000
us-gaap Interest Expense
InterestExpense
5042000
us-gaap Interest Expense
InterestExpense
4296000
CY2020Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3771000
CY2019Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
5717000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16640000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7334000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2062000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4366000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21520000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4046000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18778000
us-gaap Net Income Loss
NetIncomeLoss
-70024000
us-gaap Net Income Loss
NetIncomeLoss
-60355000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46944536
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57440885
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44052470
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68761790
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52713768
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57440885
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44052470
us-gaap Profit Loss
ProfitLoss
-70024000
us-gaap Profit Loss
ProfitLoss
-60355000
us-gaap Share Based Compensation
ShareBasedCompensation
5427000
us-gaap Share Based Compensation
ShareBasedCompensation
6806000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3279000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2469000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16640000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7334000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2106000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1856000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-7000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5231000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
913000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
500000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
200000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
678000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-593000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-552000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
32000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
911000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
543000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-825000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-596000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47308000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58111000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
588000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1637000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-588000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1637000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16205000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6502000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56201000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60676000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72406000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67178000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2044000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
71000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
464000
ocul Derivative Liability In Connection With Issuance Of Senior Convertible Notes
DerivativeLiabilityInConnectionWithIssuanceOfSeniorConvertibleNotes
16434000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3630000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
37275000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1044000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
350000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
294000
ocul Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
3201000
ocul Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
3201000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62707000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28647000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66250000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12690000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1665000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-21512000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-10659000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
378000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
350000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50017000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1826000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-36568000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5344000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1936000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4126000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
35875000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4954000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1942000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17124000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
25648000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
294000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5074000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1695000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-24453000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8258000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18619000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3169000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18778000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
11301000
us-gaap Net Income Loss
NetIncomeLoss
-70024000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453639000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70642000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition and the fair value of derivatives.  The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, and those of its customers, vendors, suppliers, and collaboration partners, will depend on future developments that are highly uncertain, subject to change and difficult to predict, including new information that may emerge concerning COVID-19, the actions taken to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;margin:0pt;">contain it or treat its impact and the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements, and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers and Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company has all cash and cash equivalents balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its products. The Company’s development programs as well as revenue from future sales of its product sales could be adversely affected by a significant interruption in the supply of any of the components of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2020, three individual customers accounted for 39%, 38% and 10% and three individual customers accounted for 40%, 30%, and 12%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue. At September 30, 2020, </span>three individual customers accounted for 44%, 35% and 11% of the Company’s total accounts receivable. No other customer accounted for more than 10% of total revenue or accounts receivable at September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2019, two individual customers accounted for 13% and 10%, and one individual customer accounted for 18%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue. At December 31, 2019, </span>three individual customers accounted for 39%, 18% and 11% of the Company’s total accounts receivable. No other customer accounted for more than 10% of total accounts receivable for the year ended December 31, 2019.</p>
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
333000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
217000
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
75000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
148000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
746000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
589000
CY2020Q3 us-gaap Inventory Net
InventoryNet
1154000
CY2019Q4 us-gaap Inventory Net
InventoryNet
954000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70642000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65414000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54437000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72406000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67178000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56201000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-16640000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5395000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5042000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
701000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1011000
CY2020Q3 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
845000
CY2019Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
849000
CY2020Q3 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
3619000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1605000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
733000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12165000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7635000
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
12124000
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
28764000
us-gaap Net Income Loss
NetIncomeLoss
-70024000
us-gaap Net Income Loss
NetIncomeLoss
-60355000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46944536
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57440885
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44052470
CY2020Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q2 ocul Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
3201000
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48327000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18778000
CY2020Q3 us-gaap Dilutive Securities
DilutiveSecurities
-3771000
CY2019Q3 us-gaap Dilutive Securities
DilutiveSecurities
-5717000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14646000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-23497000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46944536
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2019Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68761790
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52713768
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11944000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18778000
CY2020Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1069000
CY2019Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
998000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8989728
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7640661
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1936000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3169000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5427000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6806000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10974000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2020Q3 ocul Share Based Compensation Arrangement By Share Based Payment Award Nonvested Stock Options Outstanding Held By Nonemployees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedStockOptionsOutstandingHeldByNonemployees
16227

Files In Submission

Name View Source Status
0001558370-20-012870-index-headers.html Edgar Link pending
0001558370-20-012870-index.html Edgar Link pending
0001558370-20-012870.txt Edgar Link pending
0001558370-20-012870-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20200930.xsd Edgar Link pending
ocul-20200930x10q.htm Edgar Link pending
ocul-20200930x10q006.jpg Edgar Link pending
ocul-20200930x10q007.jpg Edgar Link pending
ocul-20200930x10q008.jpg Edgar Link pending
ocul-20200930x10q009.jpg Edgar Link pending
ocul-20200930x10q010.jpg Edgar Link pending
ocul-20200930x10q011.jpg Edgar Link pending
ocul-20200930x10q012.jpg Edgar Link pending
ocul-20200930x10q_htm.xml Edgar Link completed
ocul-20200930xex10d1.htm Edgar Link pending
ocul-20200930xex31d1.htm Edgar Link pending
ocul-20200930xex31d2.htm Edgar Link pending
ocul-20200930xex32d1.htm Edgar Link pending
ocul-20200930xex32d2.htm Edgar Link pending
ocul-20200930_cal.xml Edgar Link unprocessable
ocul-20200930_def.xml Edgar Link unprocessable
ocul-20200930_lab.xml Edgar Link unprocessable
ocul-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending